The Revolution Will Not Come In Pill Form

Four years ago the FDA rejected an application by drug maker Boehringer for a little pink pill, called Flibanserin. Boehringer claimed that their drug could be used to treat women with low sexual desire. The FDA rejected the drug based on a lack of evidence regarding effectiveness and concerns about side effects.

The drug passed hands, and now Sprout Pharmaceuticals has brought the drug back to the FDA, armed with two new studies, and a new marketing technique. Their new argument for why the...